This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Sepsis, Septic Shock or Cancer
and you are
over 18
years old
-
The phase for this study is not defined.
Show me locations

The purpose

The mortality induced by infections in onco-hematological patients is abnormally high at the acute phase of septic shock. Consequently, it is important to detect the population with a high risk of short term mortality among patients with a septic shock. The aim of this study is the evaluation of predictive proteic profile on the short term mortality in the acute phase of septic shock in cancer patients.

Provided treatments

  • Other: SELDI-TOF MS for plasmatic proteic profile
Tris trial is registered with FDA with number: NCT00930085. The sponsor of the trial is Institut Paoli-Calmettes and it is looking for 60 volunteers for the current phase.
Official trial title:
Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients